Overview Safety, Tolerability, and Efficacy of PresbiDrops (CSF-1), a Topical Ophthalmic Drug for Presbyopia Status: Completed Trial end date: 2017-06-01 Target enrollment: Participant gender: Summary A study to establish safety, tolerability, and efficacy of PresbiDrops (CSF-1) in presbyopic subjects. Phase: Phase 2 Details Lead Sponsor: Orasis Pharmaceuticals Ltd.